The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis

NeuroToxicology

Volumn 30, Issue 5, 2009, Pages 761-765

  Johnson, Frank O ^a   Atchison, William D ^a  

^a Center for Integrative Toxicology   (United States)

Author keywords

Amyotrophic lateral sclerosis; Gene environment; Lead; Methylmercury; Neurodegenerative disease; Organophosphates; Paralysis

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; GLUTATHIONE SYNTHASE; LEAD; MERCURY; ORGANOPHOSPHATE PESTICIDE; PESTICIDE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DISEASE ASSOCIATION; DISEASE MODEL; ENVIRONMENTAL EXPOSURE; GENOTYPE ENVIRONMENT INTERACTION; GUAM; HUMAN; INCIDENCE; INDIGENOUS PEOPLE; MEDICAL RESEARCH; NONHUMAN; PACIFIC ISLANDER; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SPORT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ENVIRONMENTAL POLLUTANTS; HUMANS; INCIDENCE; LEAD; MERCURY; PESTICIDES; PROSPECTIVE STUDIES; RISK FACTORS;

ANIMALIA; CYCADOPSIDA; PTEROPODIDAE;

EID: 70349749966     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2009.07.010     Document Type: Article

References (99)

1. Adams C.R., Ziegler D.K., and Lin J.T. Mercury intoxication simulating amyotrophic lateral sclerosis. JAMA 250 (1983) 642-643
2. Adkins S., Gan K.N., and Mody M. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 53 (1993) 598-608
3. Albalak R., McElroy R.H., Noonan G., Buchanan S., Jones R.L., Flanders W.D., et al. Blood lead levels and risk factors for lead poisoning among children in a Mexican smelting community. Arch Environ Health 58 (2003) 172-183
4. Albanito L., Lappano R., Madeo A., Chimento A., Prossnitz E.R., Cappello A.R., et al. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ Health Perspect 116 (2008) 1648-1655
5. Arvidson B. Inorganic mercury is transported from muscular nerve terminals to spinal and brainstem motoneurons. Muscle Nerve 15 (1992) 1089-1094
6. Bakir F., Damluj S.F., Amin-Zaki L., Murtadha M., Khalidi A., Al Rawi N.Y., et al. Methylmercury poisoning in Iraq. Science 181 (1973) 230-241
7. Barbeito AG, Guelfi N, Varga MR, Pehar M, Beckman J, Barbeito L, et al. Chronic low-level lead exposure increases survival of G93A SOD-1 transgenic mice [Abstract]. In: Amyotrophic lateral sclerosis: beyond the motor neuron; 2005. Available: http://iibce.edu.uy/alsmeeting/abstract.htm (Accessed December, 2008).
8. Barber T.E. Inorganic mercury intoxication reminiscent of amyotrophic lateral sclerosis. J Occup Med 20 (1978) 667-669
9. Binns H.J., LeBailly S.A., Fingar A.R., and Saunders S. Evaluation of risk assessment questions used to target blood lead screening in Illinois. Pediatrics 103 (1999) 100-106
10. Boillée S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312 (2006) 1389-1392
11. Brophy V.H., Hastings M.D., Clendenning J.B., Richter R.J., Jarvik G.P., and Furlong C.E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11 (2001) 77-84
12. Burge P., and Evans S. Mercury contamination in Arkansas gamefish. A public health perspective. J Ark Med Soc 90 (1994) 542-544
13. Campbell A.M., Williams E.R., and Barltrop D. Motor neurone disease and exposure to lead. J Neurol Neurosurg Psychiatry 33 (1970) 877-885
14. Chuu J.J., Liu S.H., and Lin-Shiau S.Y. Differential neurotoxic effects of methylmercury and mercuric sulfide in rats. Toxicol Lett 169 (2007) 109-120
15. Cox P., and Sacks O. Cycad neurotoxins, consumption of flying foxes and ALS/PDC disease in Guam. Neurology 58 (2002) 956-959
16. Cronin S., Greenway M.J., Prehn J.H., and Hardiman O. Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 78 (2007) 984-986
17. Diekstra F.P., Beleza-Meireles A., Leigh N.P., Shaw C.E., and Al-Chalabi A. Interaction between PON1 and population density in amyotrophic lateral sclerosis. Neuroreport 20 (2009) 186-190
18. Donoghue A.M. Mercury toxicity due to the smelting of placer gold recovered by mercury amalgam. Occup Med (Lond) 48 (1998) 413-415
19. Elbaz A., Dufouil C., and Alpérovitch A. Interaction between genes and environment in neurodegenerative diseases. C R Biol 330 (2007) 318-328
20. Ermilova P.I., Ermilov B.V., Levy M., Hob E., Pereira C., and Beckman S.B. Protection by dietary zinc in ALS mutant G93A SOD transgenic mice. Neurosci Lett 379 (2005) 42-46
21. Foo S.C., Khoo N.Y., Heng A., Chua L.H., Chia S.E., Ong C.N., et al. Metals in hair as biological indices for exposure. Int Arch Occup Environ Health 65 Suppl. 1 (1993) S83-S86
22. Furlong C.E., Cole T.B., Jarvik G.P., Pettan-Brewer C., Geiss G.K., Richter R.J., et al. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology 26 (2005) 651-659
23. Furlong C.E., Li W.F., Richter R.J., Shih D.M., Lusis A.J., Alleva E., et al. Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). Neurotoxicology 21 (2000) 91-100
24. Galasko D., Salmon D.P., Craig U.K., Thal L.J., Schellenberg G., and Wiederholt W. 1997-2000 Clinical features and changing patterns of neurodegenerative disorders on Guam. Neurology 58 (2002) 90-97
25. Grandjean P., White R.F., Nielsen A., Cleary D., and de Oliveira Santos E.C. Methylmercury neurotoxicity in Amazonian children downstream from gold mining. Environ Health Perspect 107 (1999) 587-591
26. Gresham L.S., Molgaard C.A., Golbeck A.L., and Smith R. Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study. Neuroepidemiology 5 (1986) 29-38
27. Groenevelda G.J., van Weenen J., de Leeuw, van Muiswinkel F.L., Veldman H., Veldinka J.H., et al. Zinc amplifies mSOD1-mediated toxicity in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Lett 352 (2003) 175-178
28. Gurney M.E. Transgenic animal models of familial amyotrophic lateral sclerosis. J Neurol 244 (1997) S15-S20
29. Haley R.W., Billecke S., and La Du B.N. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 157 (1996) 227-233
30. Haley R.W. Excess incidence of ALS in young Gulf War veterans. Neurology 61 (2003) 750-756
31. Håkansson N., Gustavsson P., Johansen C., and Floderus B. Neurodegenerative diseases in welders and other workers exposed to high levels of magnetic fields. Epidemiology 14 (2003) 420-426
32. Henderson R.F., Barr E.B., and Blackwell W.B. Response of rats to low levels of sarin. Toxicol Appl Pharmacol 184 (2002) 67-76
33. Horner R.D., Grambow S.C., Coffman C.J., Lindquist J.H., Oddone E.Z., Allen K.D., et al. Amyotrophic lateral sclerosis among 1991 Gulf War veterans: evidence for a time-limited outbreak. Neuroepidemiology 31 (2008) 28-32
34. Iwami O., Niki Y., Watanabe T., and Ikeda M. Motor neuron disease on the Kii Peninsula of Japan: cycad exposure. Neuroepidemiology 12 (1993) 307-312
35. Johnson F.O., and Atchison W.D. Potential enhanced development of paralytic phenotype in SOD1-G93a mice by methylmercury. Environmental etiologies of neurological disorders: scientific, translational and policy implications. 25th International Neurotoxicology Conference (2008)
36. Johnson F., and Atchison W. Postnatal exposure to methylmercury enhances development of paralytic phenotype in Sod1-G93a female mice. The toxicologist, supplement to Tox. Sci. 48th Annual Meeting and Expo (2009)
37. Kamel F., Umbach D.M., Stallone L., Richards M., Hu H., and Sandler D.P. Association of lead exposure with survival in amyotrophic lateral sclerosis. Environ Health Perspect 116 (2008) 943-947
38. Kamel F., Umbach D.M., Hu H., Munsat T.L., Shefner J.M., Taylor J.A., et al. Lead exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegener Dis 2 (2005) 195-201
39. Kasarskis E.J., Lindquist J.H., Coffman C.J., Grambow S.C., Feussner J.R., Allen K.D., et al. Clinical aspects of ALS in Gulf War veterans. Amyotroph Lateral Scler 10 (2009) 35-41
40. Kisby G.E., Ellison M., and Spencer P.S. Content of the neurotoxins cycasin (methylazoxymethanol beta-d-glucoside) and BMAA (beta-N-methylaminol-alanine) in cycad flour prepared by Guam Chamorros. Neurology 42 (1992) 1336-1340
41. Kurland L.T., and Mulder D.W. Age-specific incidence rates for motor neuron disease. J Neurol Neurosurg Psychiatry 50 1 (1987) 115-116
42. Kurlander H.M., and Patten B.M. Metals in spinal cord tissue of patients dying of motor neuron disease. Ann Neurol 6 (1979) 21-24
43. Landers J.E., Shi L., Cho T.J., Glass J.D., Shaw C.E., Leigh P.N., et al. A common haplotype within the PON1 promoter region is associated with sporadic ALS. Amyotroph Lateral Scler 9 (2008) 306-314
44. Leigh P.N., Whitwell H., Garofalo O., Buller J., Swash M., et al. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain 114 (1991) 775-788
45. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10 (2000) 767-779
46. Li C.Y., and Sung F.C. Association between occupational exposure to power frequency electromagnetic fields and amyotrophic lateral sclerosis: a review. Am J Ind Med 43 (2003) 212-220
47. Lindgren K.N., Ford D.P., and Bleecker M.L. Pattern of blood lead levels over working lifetime and neuropsychological performance. Arch Environ Health 58 (2003) 373-379
48. Longstreth W.T., McGuire V., Koepsell T.D., Wang Y., and van Belle G. Risk of amyotrophic lateral sclerosis and history of physical activity: a population-based case-control study. Arch Neurol 5 (1998) 201-206
49. Mackness B., Durrington P.N., and Mackness M.I. Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. Biochem Biophys Res Commun 276 (2000) 729-733
50. Martin M.A., and Hussain K. Striatal neurochemical changes and motor dysfunction in mipafox-treated animals. Methods Find Exp Clin Pharmacol 7 (1985) 79-81
51. McGuire V., Longstreth Jr. W.T., Nelson L.M., Koepsell T.D., Checkoway H., Morgan M.S., et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. Am J Epidemiol 145 (1997) 1076-1088
52. Mahaffey K.R., Clickner R.P., and Bodurow C.C. Blood organic mercury and dietary mercury intake: National Health and Nutrition Examination Survey, 1999 and 2000. Environ Health Perspect 112 (2004) 562-570
53. Miranda M.L., Overstreet A., Galeano M., Tassone E., Allen K.D., and Horner R.D. Spatial analysis of the etiology of amyotrophic lateral sclerosis among 1991 Gulf War veterans. Neurotoxicology 29 (2008) 964-970
54. Morahan J.M., Yu B., Trent R.J., and Pamphlett R. A gene-environment study of the paraoxonase 1 gene and pesticides in amyotrophic lateral sclerosis. Neurotoxicology 28 (2007) 532-540
55. Morahan J.M., Yu B., Trent R.J., and Pamphlett R. A gene-environment study of the paraoxonase 1 gene and pesticides in amyotrophic lateral sclerosis. Neurotoxicology 28 (2006) 532-540
56. Morahan J.M., and Pamphlett R. Amyotrophic lateral sclerosis and exposure to environmental toxins: an Australian case-control study. Neuroepidemiology 27 (2006) 130-135
57. Moriwaka F., Tashiro K., Doi R., Satoh H., and Fukuchi Y. A clinical evaluation of the inorganic mercurialism-its pathogenic relation to amyotrophic lateral sclerosis. Rinsho Shinkeigaku 31 (1991) 885-887
58. Morrison B.M., and Morrison J.H. Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: a putative mechanism of degeneration. Brain Res Rev 29 (1999) 121-135
59. Murch S.J., Cox P.A., Banack S.A., Steele J.C., and Sacks O.W. Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand 110 (2004) 267-269
60. Mutter J., and Yeter D. Kawasaki's disease, acrodynia, and mercury. Curr Med Chem 15 (2008) 3000-3010
61. Nelson L.M., McGuire V., Longstreth Jr. W.T., and Matkin C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol 151 (2000) 156-163
62. Pamphlett R., and Waley P. Mercury in human spinal motor neurons. Acta Neuropathol (Berl) 96 (1998) 515-519
63. Pierce-Ruhland R., and Patten B.M. Muscle metals in motor neuron disease. Ann Neurol 8 (1980) 193-195
64. Plato C.C., Galasko D., Garruto R.M., Plato M., Gamst A., Craig U.K., et al. ALS and PDC of Guam: forty-year follow-up. Neurology 58 5 (2003) 765-773 12
65. Plato C.C., Garruto R.M., Galasko D., Craig U.K., Plato M., Gamst A., et al. Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am J Epidemiol 157 (2003) 149-157
66. Poulletier de Gannes F., Ruffie G., Taxile M., Ladeveze E., Hurtier A., Haro E., et al. Amyotrophic lateral sclerosis (ALS) and extremely-low frequency (ELF) magnetic fields: a study in the SOD-1 transgenic mouse model. Amyotroph Lateral Scler (2008) 1-4
67. Praline J., Guennoc A., Limousin N., Hallak H., de Toffol B., and Corcia P. Case report; ALS and mercury intoxication: a relationship?. Clin Neurol Neurosurg 109 (2007) 880-883
68. Provinciali L., and Giovagnoli A.R. Antecedent events in amyotrophic lateral sclerosis: do they influence clinical onset and progression?. Neuroepidemiology 9 (1990) 255-262
69. Qureshi M.M., Hayden D., Urbinelli L., Ferrante K., Newhall K., Myers D., et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler 7 (2008) 173-182
70. Richter R.J., Jarvik G.P., and Furlong C.E. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 235 (2009) 1-9
71. Roscoe R.J., Ball W., Curran J.J., DeLaurier C., Falken M.C., Fitchett R., et al. Adult blood lead epidemiology and surveillance-United States, 1998-2001. MMWR Surveill Summ 13 (2002) 1-10
72. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
73. Rustam H., Von Burg R., Amin-Zaki L., and El Hassani S. Evidence for a neuromuscular disorder in methylmercury poisoning. Arch Environ Health 30 (1975) 190-195
74. Sacks O.W. Guam ALS-PDC: possible causes. Science 262 (1993) 826
75. Saeed M., Siddique N., Hung W.Y., Usacheva E., Liu E., Sufit R.L., et al. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 67 (2006) 771-776
76. Schmidt S., Allen K.D., Loiacono V.T., Norman B., Stanwyck C.L., Nord K.M., et al. Genes and environmental exposures in veterans with amyotrophic lateral sclerosis: the GENEVA study. Rationale, study design and demographic characteristics. Neuroepidemiology 30 (2008) 191-204
77. Schwarz S., Husstedt I., Bertram H.P., and Kuchelmeister K. Amyotrophic lateral sclerosis after accidental injection of mercury. J Neurol Neurosurg Psychiatry 60 (1996) 698
78. Schymick J.C., Talbot K., and Traynor B.J. Genetics of sporadic amyotrophic lateral sclerosis. Hum Mol Genet 16 (2007) (Review Issue 2)
79. Sejvar J.J., Holman R.C., Bresee J.S., Kochanek K.D., and Schonberger L.B. Amyotrophic lateral sclerosis mortality in the United States, 1979-2000. Neuroepidemiology 25 (2005) 144-152
80. Shoesmith C.L., and Strong M.J. Amyotrophic lateral sclerosis: update for family physicians. Can Fam Physician 52 (2006) 1563-1569
81. Sienko D.G., Davis J.P., Taylor J.A., and Brooks B.R. Amyotrophic lateral sclerosis. A case-control study following detection of a cluster in a small Wisconsin community. Arch Neurol 47 (1990) 38-41
82. Simpson C.L., and Al-Chalabi A. Amyotrophic lateral sclerosis as a complex genetic disease. Biochim Biophys Acta 1762 (2006) 973-985
83. Sirivarasai J., Kaojarern S., Yoovathaworn K., and Sura T. Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects. Chem Biol Interact 20 (2007) 184-192
84. Slowik A., Tomik B., Wolkow P.P., Partyka D., Turaj W., Malecki M.T., et al. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 67 (2006) 766-770
85. Spencer P., Palmer V., Herman A., and Asmedi A. Cycad use and motor neurone disease in Irian Jaya. Lancet 2 (1987) 1462-1463
86. Stozická Z., Zilka N., and Novák M. Risk and protective factors for sporadic Alzheimer's disease. Acta Virol 51 (2007) 205-222
87. Sutedja N.A., Veldink J.H., Fischer K., Kromhout H., Heederik D., Huisman M.H., et al. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler 8 (2008) 1-20
88. Thakur J.S., Rao B.T., Rajwanshi A., Parwana H.K., and Kumar R. Epidemiological study of high cancer among rural agricultural community of Punjab in Northern India. Int J Environ Res Public Health 5 (2008) 399-407
89. The Riegle Report (accessed January 1, 2008). US chemical and biological warfare-related dual use exports to Iraq and their possible impact on health consequences of the Gulf War. Committee on Banking Housing and Urban Affairs with respect to export administration; 1994. http://www.gulfweb.org/bigdoc/report/riegle1.html.
90. Valdmanis P.N., Kabashi E., Dyck A., Hince P., Lee J., Dion P., et al. Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. Neurology 71 (2008) 514-520
91. Veldink J.H., Kalmijn S., Groeneveld G.J., Titulaer M.J., Wokke J.H., and van den Berg L.H. Physical activity and the association with sporadic ALS. Neurology 64 (2005) 241-245
92. Waring S.C., Esteban-Santillan C., Reed D.M., Craig U.K., Labarthe D.R., Petersen R.C., et al. Incidence of amyotrophic lateral sclerosis and of the parkinsonism-dementia complex of Guam, 1950-1989. Neuroepidemiology 23 (2004) 192-200
93. Worms P.M. The epidemiology of motor neuron disease: a review of recent studies. J Neurol Sci 191 (2001) 3-9
94. Weiss B., Amler S., and Amler W.R. Pesticides. Pediatrics 113 (2004)
95. Weisskopf M.G., Morozova N., O'Reilly E.J., McCullough M.L., Calle E.E., Thun M.J., et al. Prospective study of chemical exposures and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 80 (2009) 558-561
96. Weisskopf M.G., McCullough M.L., Calle E.E., Thun M.J., Cudkowicz M., and Ascherio A. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epidemiol 160 (2004) 26-33
97. Wills A.M., Landers J.E., Zhang H., Richter R.J., Caraganis A.J., Cudkowicz M.E., et al. Paraoxonase 1(PON1) organophosphate hydrolysis is not reduced in ALS. Neurology 70 (2008) 929-934
98. Yan D., Xiao C., Ma F.L., Wang L., Luo Y.Y., Liu J., et al. Excitatory effects of low-level lead exposure on action potential firing of pyramidal neurons in CA1 region of rat hippocampal slices. J Neurosci Res 86 (2008) 3665-3673
99. Zumstein V., and Regli F. Amyotrophic lateral sclerosis. Epidemiologic study. Schweiz Rundsch Med Prax 14 (1982) 1424-1427